“Global Attention Deficit Hyperactivity Disorder Drugs Market is estimated to reach $17bn by 2024” says Visiongain report

31 October 2019
Pharma

Visiongain has launched a new pharma report Attention Deficit Hyperactivity Disorder Drugs Market: Amphetamine, Methylphenidate Hydrochloride, Dexymethylphenidate, Lisdexamfetamine, Atomoxetine, Guanfacine, Clonidine, Stimulants, No-stimulants, Adults, Children, Retail Pharmacy, Hospital Pharmacy.

The global attention deficit hyperactivity disorder is anticipated to witness strong growth during the forecast period. Factors such as the growing prevalence of the ADHD cases in adults and children, growing awareness coupled with support from the government as well as rising regulatory approvals will drive market growth.

The lead analyst of the report commented "The global attention deficit disorder market is one that is driven by innovation. This is vital for maintaining the rich pipeline of ADHD drugs seen in the market today. There is increasing focus to identify and treat ADHD that currently are undertreated and try to serve these neglected markets. This creates a strong platform for both start-ups and larger pharmaceutical companies to create new drugs that are not already on the market. This prevents stagnation within the market and will help drive the growth of attention deficit disorder market."

Leading companies featured in the report include Eli Lilly, Johnson and Johnson, Lupin Limited, Mallinckrodt & Co., Neos Therapeutics, Pfizer Inc., Purdue Pharma L.P., Takeda Pharmaceuticals and other companies.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Biopharmaceuticals Contract Manufacturing Market Report 2022-2032

Ageing population will be more susceptible to such diseases and is one of the key factors driving the growth of the global biological drugs market. In most of the developed world, the share of elderly population is almost touching a quarter of the population.

26 January 2022

Read

Visiongain Publishes Topical Drug Delivery Market Report 2022-2032

Some of the factors driving the market growth are the increasing prevalence of skin and eye diseases, high incidences of burn incidences and the growing prevalence of diabetes.

26 January 2022

Read

Visiongain Publishes Decentralized Clinical Trials Market Report 2022-2032

The growing adoption advanced e-clinical solutions, rising focus on clinical research, increasing investment in R&D, and adoption of decentralized clinical trials by biopharmaceutical companies are some of the major factors that drive the growth of the global decentralized clinical trials market.

24 January 2022

Read

Visiongain Publishes Nasal Drug Delivery Technology Market Report 2022-2032

The nasal drug delivery market will expand rapidly due to rising patient preference for nasal medication delivery due to ease of administration and efficacy, increased self-administration practises, and increased demand for home healthcare equipment.

18 January 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever